A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
A form of RHABDOMYOSARCOMA arising primarily in the head and neck, especially the orbit, of children below the age of 10. The cells are smaller than those of other rhabdomyosarcomas and are of two basic cell types: spindle cells and round cells. This cancer is highly sensitive to chemotherapy and has a high cure rate with multi-modality therapy. (From Holland et al., Cancer Medicine, 3d ed, p2188)
A form of RHABDOMYOSARCOMA occurring mainly in adolescents and young adults, affecting muscles of the extremities, trunk, orbital region, etc. It is extremely malignant, metastasizing widely at an early stage. Few cures have been achieved and the prognosis is poor. "Alveolar" refers to its microscopic appearance simulating the cells of the respiratory alveolus. (Holland et al., Cancer Medicine, 3d ed, p2188)
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
A paired box transcription factor that is involved in EMBRYONIC DEVELOPMENT of the CENTRAL NERVOUS SYSTEM and SKELETAL MUSCLE.
A family of transcription factors that control EMBRYONIC DEVELOPMENT within a variety of cell lineages. They are characterized by a highly conserved paired DNA-binding domain that was first identified in DROSOPHILA segmentation genes.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Neoplasms of the bony orbit and contents except the eyeball.
Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
A mixed mesenchymal tumor composed of two or more mesodermal cellular elements not commonly associated, not counting fibrous tissue as one of the elements. Mesenchymomas are widely distributed in the body and about 75% are malignant. (Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.
A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.
A subclass of winged helix DNA-binding proteins that share homology with their founding member fork head protein, Drosophila.
The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.
An intermediate filament protein found predominantly in smooth, skeletal, and cardiac muscle cells. Localized at the Z line. MW 50,000 to 55,000 is species dependent.
A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.
Tumors or cancer of the VAGINA.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.
A sex cord-gonadal stromal tumor consists of LEYDIG CELLS; SERTOLI CELLS; and FIBROBLASTS in varying proportions and degree of differentiation. Most such tumors produce ANDROGENS in the Leydig cells, formerly known as androblastoma or arrhenoblastoma. Androblastomas occur in the TESTIS or the OVARY causing precocious masculinization in the males, and defeminization, or virilization (VIRILISM) in the females. In some cases, the Sertoli cells produce ESTROGENS.
A myogenic regulatory factor that controls myogenesis. Myogenin is induced during differentiation of every skeletal muscle cell line that has been investigated, in contrast to the other myogenic regulatory factors that only appear in certain cell types.
A myogenic regulatory factor that controls myogenesis. Though it is not clear how its function differs from the other myogenic regulatory factors, MyoD appears to be related to fusion and terminal differentiation of the muscle cell.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A cell line derived from cultured tumor cells.
Thoracic neoplasms are a broad category of abnormal growths or tumors that originate within the thorax, encompassing malignant (cancerous) and benign (non-cancerous) forms, which can affect structures such as the lungs, pleura, mediastinum, and chest wall.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Tumors or cancer of the pelvic region.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
The GENETIC RECOMBINATION of the parts of two or more GENES resulting in a gene with different or additional regulatory regions, or a new chimeric gene product. ONCOGENE FUSION includes an ONCOGENE as at least one of the fusion partners and such gene fusions are often detected in neoplastic cells and are transcribed into ONCOGENE FUSION PROTEINS. ARTIFICIAL GENE FUSION is carried out in vitro by RECOMBINANT DNA technology.
A species of ENTEROVIRUS infecting humans and containing 10 serotypes, mostly coxsackieviruses.
A malignant neoplasm of the lung composed chiefly or entirely of immature undifferentiated cells (i.e., blast forms) with little or virtually no stroma. (From Stedman, 25th ed)
A CCN protein family member found at high levels in NEPHROBLASTOMA cells. It is found both intracellularly and in the EXTRACELLULAR MATRIX and may play a role in the regulation of CELL PROLIFERATION and EXTRACELLULAR MATRIX synthesis.

Prenatal sonographic features of embryonal rhabdomyosarcoma. (1/128)

We describe a case of fetal rhabdomyosarcoma detected during the third trimester of pregnancy by prenatal sonography. At 33 weeks' gestation, sonography performed because of suspected polyhydramnios showed a solid mass of 120 x 54 mm arising from the anterior wall of the fetal thoracic cage. Another mass within the left maxillary area which originated from the left orbital floor was also detected. In the abdomen, there were multiple round masses in and around the liver. As the previous scan at 28 weeks had appeared normal, the multiple masses which became visible and enlarged rapidly in different locations led us to believe that there was fetal cancer. The most likely diagnosis was rhabdomyosarcoma (which was later confirmed), because it is the most prevalent soft-tissue tumor in children and may develop within or outside muscle anywhere in the body and at any age. Two other reported cases which were detected by prenatal ultrasound examination are also discussed.  (+info)

Differentiated embryonal rhabdomyosarcoma in a cow. (2/128)

An embryonal rhabdomyosarcoma was found in the pleura of a 2-year-old Holstein cow after first delivery. The most predominant cells in the tumor were relatively small in size, but considerable numbers of more differentiated cells of larger sizes mingled with the small cells. The most differentiated cells were characterized by multinucleation, abundant cytoplasm containing cross-striated fibrils, intense immunoreactivity for desmin, and weak or negative reactivity for vimentin. Such cells, lacking mitotic activity and displaying weak or no reactivity for proliferating cell nuclear antigen, were considered to be malignant counterparts of myotubes or muscle fibers. This neoplasm seems to follow normal skeletal muscle embryogenesis, and to be capable of differentiation into the final stage of muscle development.  (+info)

Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females. (3/128)

Sarcoma botryoides of the cervix is an extremely rare tumour and seems to be associated with a better prognosis than its vaginal counterpart. Recent studies have suggested that it is possible to limit surgery to local excision in stage I cases. We report three cases of young subjects treated successfully with polypectomy or diathermy loop excision followed by adjuvant chemotherapy. One patient had a local recurrence which was treated with further local excision. All subjects remain alive without evidence of recurrence and with normal menstrual function 36, 38 and 38 months following initial diagnosis. A conservative surgical approach to early cervical sarcoma botryoides is possible. The efficacy of adjuvant chemotherapy and the regimen of choice still need to be investigated.  (+info)

The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin. (4/128)

The protein synthetic machinery is activated by diverse genetic alterations during tumor progression in vivo and represents an attractive target for cancer therapy. We show that rapamycin inhibits the induction of transformed foci in vitro by GLI, a transcription factor that functions in the sonic hedgehog-patched pathway in tumors. In control cells, which were nontransformed epithelioid RK3E cells and derivative c-MYC- or RAS-transformed sister cell lines, rapamycin inhibits mTOR and mTOR-dependent activities but increases global protein synthesis, perhaps by activating a feedback mechanism. In GLI-transformed cells, rapamycin inhibits global protein synthesis and turnover and prevents cellular proliferation. In contrast to its effects on protein synthesis, rapamycin affects bromodeoxyuridine incorporation and cell cycle occupancy of GLI cells and control cells to a similar extent. Rare, variant GLI cells isolated by selection in rapamycin are also drug-resistant for protein metabolism and for cell cycle progression through G1. Our results indicate that sensitivity to rapamycin can be induced by a specific oncogene and that inhibition of global protein metabolism is linked to the rapamycin-sensitive phenotype.  (+info)

Perinatal management of a neonate with airway obstruction caused by rhabdomyosarcoma of the tongue. (5/128)

Intra-oral masses in neonates can seriously compromise the airway, potentially causing hypoxia and death if not recognized and managed appropriately. We report a case in which an intra-oral mass was diagnosed on antenatal ultrasound scan. Preparation for delivery involved a multidisciplinary team approach, with a strategy for management at delivery. The child was delivered by elective Caesarean section and had a patent airway. A tracheostomy was performed immediately after delivery. The infant underwent a debulking procedure 3 weeks after birth. A histological diagnosis of embryonal rhabdomyosarcoma was made and a course of chemotherapy commenced. The child had a partial response to treatment with considerable shrinkage of the tongue mass. We discuss the management options in neonates with intra-oral masses to provide an adequate airway and maintain fetal oxygenation. The differential diagnosis of fetal oral masses is reviewed.  (+info)

Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. (6/128)

PURPOSE: To compare failure-free survival (FFS) and survival for patients with local or regional embryonal rhabdomyosarcoma treated on the Intergroup Rhabdomyosarcoma Study (IRS)-IV with that of comparable patients treated on IRS-III. PATIENTS AND METHODS: Patients were retrospectively classified as low- or intermediate-risk. Low-risk patients were defined as those with primary tumors at favorable sites, completely resected or microscopic residual, or orbit/eyelid primaries with gross residual disease and tumors less than 5 cm at unfavorable sites but completely resected. Intermediate-risk patients were all other patients with local or regional tumors. RESULTS: Three-year FFS improved from 72% on IRS-III to 78% on IRS-IV for patients with intermediate-risk embryonal rhabdomyosarcoma (P =.02). Subset analysis revealed two groups that benefited most from IRS-IV therapy. FFS at 3 years for patients with resectable node-positive or unresectable (group III) embryonal rhabdomyosarcoma arising at certain favorable sites (head and neck [not orbit/eyelid or parameningeal] and genitourinary [not bladder or prostate]) improved from 72% on IRS-III to 92% on IRS-IV (P =.01). Similarly, 3-year FFS for patients with completely resected tumor or with only microscopic disease remaining (group I or II) at unfavorable sites improved from 71% on IRS-III to 86% on IRS-IV (P =.04). Only patients with unresectable embryonal rhabdomyosarcoma (group III) at unfavorable sites had no improvement in outcome on IRS-IV (3-year FFS for IRS-III and IRS-IV, 72% and 75%, respectively; P =.31). CONCLUSION: IRS-IV therapy benefited certain subgroups of patients with intermediate-risk embryonal rhabdomyosarcoma. A doubling of the intensity of cyclophosphamide (or ifosfamide equivalent) dosing per cycle between IRS-III and IRS-IV is thought to be a key contributing factor for this improvement.  (+info)

Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues. (7/128)

Myogenin belongs to a group of myogenic regulatory proteins whose expression determines commitment and differentiation of primitive mesenchymal cells into skeletal muscle. The expression of myogenin has been demonstrated to be extremely specific for rhabdomyoblastic differentiation, which makes it a useful marker in the differential diagnosis of rhabdomyosarcomas (RMS) from other malignant small round cell tumors of childhood. Commercially available antibodies capable of detecting myogenin in routinely processed formalin-fixed paraffin-embedded (FFPE) tissue are now available. In this study, we evaluated myogenin expression using the monoclonal myf-4 antibody (Novocastra Labs) on FFPE in a large number of pediatric tumors in order to define the clinical utility of this marker. A total of 119 tumors were studied. These included 48 alveolar RMS (ARMS), 20 embryonal RMS (ERMS), one spindle cell RMS, 16 Ewing's sarcomas (ES), six nephroblastomas, two ectomesenchymomas, seven precursor hematopoietic neoplasms, five olfactory neuroblastomas, three neuroblastomas, six desmoplastic small round cell tumors, and five rhabdoid tumors. Distinct nuclear staining for myogenin was noted in all 69 RMS. Notably, the number of positive tumor cells differed between the ARMS and ERMS. In ARMS, the majority of tumor cells (75 to 100%) were positive, in contrast to ERMS, in which the positivity ranged from rare + to 25% in all but three tumors. Additionally, myogenin positivity was seen in two of two ectomesenchymomas and in two nephroblastomas with myogenous differentiation. All other tumors were clearly negative. Our results indicate that staining for myogenin is an extremely reliable and specific marker for rhabdomyoblastic differentiation. It gives consistent and easily interpretable results in routinely fixed tissues.  (+info)

High-dose thiotepa and hematopoietic stem cell transplantation in pediatric malignant mesenchymal tumors: a phase II study. (8/128)

The prognosis of metastatic malignant mesenchymal tumors (MMT) remains poor. Given the chemosensitivity of these neoplasms, a phase II study of high-dose thiotepa (HDT) was performed to evaluate the efficacy of this drug in this particular subset of pediatric tumors. Between 1986 and 1998, 18 patients, previously treated with conventional therapy for metastatic or refractory MMT, entered the study. Thiotepa was administered at a daily dose of 300 mg/m2 for 3 consecutive days. Hematopoietic stem cell rescue, consisting of bone marrow transplantation or peripheral stem cell transplantation, was performed 2 days after completion of HDT. A response exceeding 50% was observed in 6/18 patients (response rate 33%). Toxicity was severe but never led to death. HDT used at a dose of 900 mg/m2 yields measurable anti-tumor activity in previously treated patients. The next step in these particularly poor prognosis metastatic MMT will be to investigate HDT combined with other drugs, known to be efficient at high doses.  (+info)

Rhabdomyosarcoma is a type of cancer that develops in the body's soft tissues, specifically in the muscle cells. It is a rare and aggressive form of sarcoma, which is a broader category of cancers that affect the connective tissues such as muscles, tendons, cartilages, bones, blood vessels, and fatty tissues.

Rhabdomyosarcomas can occur in various parts of the body, including the head, neck, arms, legs, trunk, and genitourinary system. They are more common in children than adults, with most cases diagnosed before the age of 18. The exact cause of rhabdomyosarcoma is not known, but genetic factors and exposure to radiation or certain chemicals may increase the risk.

There are several subtypes of rhabdomyosarcoma, including embryonal, alveolar, pleomorphic, and spindle cell/sclerosing. The type and stage of the cancer determine the treatment options, which may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. Early diagnosis and prompt treatment are crucial for improving the prognosis and long-term survival rates.

Rhabdomyosarcoma, embryonal is a type of soft tissue sarcoma, which is a cancer that develops in the body's connective tissues, such as muscles, tendons, ligaments, and cartilage. Specifically, embryonal rhabdomyosarcoma is a subtype of rhabdomyosarcoma that arises from cells that are in the process of becoming muscle cells. This type of cancer typically affects children, with most cases diagnosed before the age of 10.

Embryonal rhabdomyosarcoma can develop in various parts of the body, including the head and neck, genitourinary tract (reproductive and urinary organs), and extremities. The tumors are often aggressive and fast-growing, but they can be treated with a combination of surgery, radiation therapy, and chemotherapy.

The medical definition of embryonal rhabdomyosarcoma is: "A malignant neoplasm composed of small, round to avoid cells with hyperchromatic nuclei and scant cytoplasm, often arranged in a loose, fascicular pattern. It arises from primitive muscle cells and typically affects children and adolescents. The tumor can develop in various parts of the body, including the head and neck, genitourinary tract, and extremities."

Alveolar Rhabdomyosarcoma (ARMS) is a type of soft tissue sarcoma, which is a rare cancer that affects the muscles and connective tissues. ARMS is characterized by the presence of specific genetic alterations involving the PAX3 or PAX7 genes, which are fused with the FOXO1 gene. These genetic changes lead to the formation of abnormal proteins that promote uncontrolled cell growth and division, resulting in the development of tumors.

ARMS typically affects children and adolescents, although it can occur in adults as well. The most common sites for ARMS include the extremities, trunk, head, and neck. The alveolar subtype is named for its histological resemblance to lung tissue, with tumors forming small, thin-walled cavities or spaces that look like the air sacs (alveoli) in the lungs.

ARMS tends to be more aggressive than other types of rhabdomyosarcoma and has a higher risk of metastasis (spreading to other parts of the body). Treatment usually involves a combination of surgery, radiation therapy, and chemotherapy. The prognosis for ARMS depends on several factors, including the patient's age, the size and location of the tumor, and the extent of spread at the time of diagnosis.

Muscle neoplasms are abnormal growths or tumors that develop in the muscle tissue. They can be benign (non-cancerous) or malignant (cancerous). Benign muscle neoplasms are typically slow-growing and do not spread to other parts of the body, while malignant muscle neoplasms, also known as soft tissue sarcomas, can grow quickly, invade nearby tissues, and metastasize (spread) to distant parts of the body.

Soft tissue sarcomas can arise from any of the muscles in the body, including the skeletal muscles (voluntary muscles that attach to bones and help with movement), smooth muscles (involuntary muscles found in the walls of blood vessels, digestive tract, and other organs), or cardiac muscle (the specialized muscle found in the heart).

There are many different types of soft tissue sarcomas, each with its own set of characteristics and prognosis. Treatment for muscle neoplasms typically involves a combination of surgery, radiation therapy, and chemotherapy, depending on the type, size, location, and stage of the tumor.

PAX7 is a transcription factor that belongs to the PAX (paired box) family of proteins, which are characterized by the presence of a paired domain that binds to DNA. Specifically, PAX7 contains two DNA-binding domains: a paired domain and a homeodomain.

PAX7 is primarily expressed in satellite cells, which are muscle stem cells responsible for postnatal muscle growth, maintenance, and regeneration. PAX7 plays a critical role in the self-renewal and survival of satellite cells, and its expression is required for their activation and differentiation into mature muscle fibers.

As a transcription factor, PAX7 binds to specific DNA sequences in the regulatory regions of target genes and regulates their expression. This regulation can either activate or repress gene transcription, depending on the context and other factors that interact with PAX7.

PAX7 has been implicated in various muscle-related diseases, including muscular dystrophies and muscle wasting disorders. Its expression is often downregulated in these conditions, leading to a decrease in satellite cell function and muscle regeneration capacity. Therefore, understanding the role of PAX7 in muscle biology and disease has important implications for developing new therapies for muscle-related diseases.

Paired box (PAX) transcription factors are a group of proteins that regulate gene expression during embryonic development and in some adult tissues. They are characterized by the presence of a paired box domain, a conserved DNA-binding motif that recognizes specific DNA sequences. PAX proteins play crucial roles in various developmental processes, such as the formation of the nervous system, eyes, and pancreas. Dysregulation of PAX genes has been implicated in several human diseases, including cancer.

Soft tissue neoplasms refer to abnormal growths or tumors that develop in the soft tissues of the body. Soft tissues include muscles, tendons, ligaments, fascia, nerves, blood vessels, fat, and synovial membranes (the thin layer of cells that line joints and tendons). Neoplasms can be benign (non-cancerous) or malignant (cancerous), and their behavior and potential for spread depend on the specific type of neoplasm.

Benign soft tissue neoplasms are typically slow-growing, well-circumscribed, and rarely spread to other parts of the body. They can often be removed surgically with a low risk of recurrence. Examples of benign soft tissue neoplasms include lipomas (fat tumors), schwannomas (nerve sheath tumors), and hemangiomas (blood vessel tumors).

Malignant soft tissue neoplasms, on the other hand, can grow rapidly, invade surrounding tissues, and may metastasize (spread) to distant parts of the body. They are often more difficult to treat than benign neoplasms and require a multidisciplinary approach, including surgery, radiation therapy, and chemotherapy. Examples of malignant soft tissue neoplasms include sarcomas, such as rhabdomyosarcoma (arising from skeletal muscle), leiomyosarcoma (arising from smooth muscle), and angiosarcoma (arising from blood vessels).

It is important to note that soft tissue neoplasms can occur in any part of the body, and their diagnosis and treatment require a thorough evaluation by a healthcare professional with expertise in this area.

Orbital neoplasms refer to abnormal growths or tumors that develop in the orbit, which is the bony cavity that contains the eyeball, muscles, nerves, fat, and blood vessels. These neoplasms can be benign (non-cancerous) or malignant (cancerous), and they can arise from various types of cells within the orbit.

Orbital neoplasms can cause a variety of symptoms depending on their size, location, and rate of growth. Common symptoms include protrusion or displacement of the eyeball, double vision, limited eye movement, pain, swelling, and numbness in the face. In some cases, orbital neoplasms may not cause any noticeable symptoms, especially if they are small and slow-growing.

There are many different types of orbital neoplasms, including:

1. Optic nerve glioma: a rare tumor that arises from the optic nerve's supportive tissue.
2. Orbital meningioma: a tumor that originates from the membranes covering the brain and extends into the orbit.
3. Lacrimal gland tumors: benign or malignant growths that develop in the lacrimal gland, which produces tears.
4. Orbital lymphangioma: a non-cancerous tumor that arises from the lymphatic vessels in the orbit.
5. Rhabdomyosarcoma: a malignant tumor that develops from the skeletal muscle cells in the orbit.
6. Metastatic tumors: cancerous growths that spread to the orbit from other parts of the body, such as the breast, lung, or prostate.

The diagnosis and treatment of orbital neoplasms depend on several factors, including the type, size, location, and extent of the tumor. Imaging tests, such as CT scans and MRI, are often used to visualize the tumor and determine its extent. A biopsy may also be performed to confirm the diagnosis and determine the tumor's type and grade. Treatment options include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Urogenital neoplasms refer to abnormal growths or tumors that occur in the urinary and genital organs. These can include various types of cancer, such as bladder cancer, kidney cancer, prostate cancer, testicular cancer, cervical cancer, ovarian cancer, and others. Some urogenital neoplasms may be benign (non-cancerous), while others are malignant (cancerous) and can spread to other parts of the body.

The term "urogenital" refers to the combined urinary and genital systems in the human body. The urinary system includes the kidneys, ureters, bladder, and urethra, which are responsible for filtering waste from the blood and eliminating it as urine. The genital system includes the reproductive organs such as the ovaries, fallopian tubes, uterus, vagina, prostate gland, testicles, and penis.

Urogenital neoplasms can cause various symptoms depending on their location and size. Common symptoms include blood in urine, pain during urination, difficulty urinating, abnormal discharge, lumps or swelling in the genital area, and unexplained weight loss. If you experience any of these symptoms, it is important to consult a healthcare professional for further evaluation and treatment.

Sarcoma is a type of cancer that develops from certain types of connective tissue (such as muscle, fat, fibrous tissue, blood vessels, or nerves) found throughout the body. It can occur in any part of the body, but it most commonly occurs in the arms, legs, chest, and abdomen.

Sarcomas are classified into two main groups: bone sarcomas and soft tissue sarcomas. Bone sarcomas develop in the bones, while soft tissue sarcomas develop in the soft tissues of the body, such as muscles, tendons, ligaments, fat, blood vessels, and nerves.

Sarcomas can be further classified into many subtypes based on their specific characteristics, such as the type of tissue they originate from, their genetic makeup, and their appearance under a microscope. The different subtypes of sarcoma have varying symptoms, prognoses, and treatment options.

Overall, sarcomas are relatively rare cancers, accounting for less than 1% of all cancer diagnoses in the United States each year. However, they can be aggressive and may require intensive treatment, such as surgery, radiation therapy, and chemotherapy.

Mesenchymoma is a very rare type of tumor that contains a mixture of different types of mesenchymal tissues, such as muscle, fat, bone, cartilage, or fibrous tissue. It typically occurs in children and young adults, and can be found in various parts of the body, including the head, neck, retroperitoneum (the area behind the abdominal cavity), and the limbs.

Mesenchymomas are usually slow-growing and may not cause any symptoms until they reach a large size. Treatment typically involves surgical removal of the tumor, but radiation therapy or chemotherapy may also be used in some cases. The prognosis for mesenchymoma depends on several factors, including the location and size of the tumor, the patient's age and overall health, and the specific types of tissue that are present in the tumor.

Ewing sarcoma is a type of cancer that originates in bones or the soft tissues surrounding them, such as muscles and tendons. It primarily affects children and adolescents, although it can occur in adults as well. The disease is characterized by small, round tumor cells that typically grow quickly and are prone to metastasize (spread) to other parts of the body, most commonly the lungs, bones, and bone marrow.

Ewing sarcoma is caused by a genetic abnormality, specifically a chromosomal translocation that results in the fusion of two genes, EWSR1 and FLI1. This gene fusion leads to the formation of an abnormal protein that disrupts normal cell growth and division processes, ultimately resulting in cancer.

Symptoms of Ewing sarcoma can vary depending on the location and size of the tumor but may include pain or swelling in the affected area, fever, fatigue, and weight loss. Diagnosis typically involves imaging studies such as X-rays, CT scans, or MRI scans to locate the tumor, followed by a biopsy to confirm the presence of cancer cells. Treatment may involve surgery, radiation therapy, chemotherapy, or a combination of these approaches, depending on the stage and location of the disease.

Human chromosome pair 13 consists of two rod-shaped structures present in the nucleus of each cell in the human body. Each chromosome is made up of DNA tightly coiled around histone proteins, forming a complex structure called a chromatin.

Chromosomes carry genetic information in the form of genes, which are sequences of DNA that code for specific traits and functions. Human cells typically have 23 pairs of chromosomes, for a total of 46 chromosomes. Chromosome pair 13 is one of the autosomal pairs, meaning it is not a sex chromosome (X or Y).

Chromosome pair 13 contains several important genes that are associated with various genetic disorders, such as cri-du-chat syndrome and Phelan-McDermid syndrome. Cri-du-chat syndrome is caused by a deletion of the short arm of chromosome 13 (13p), resulting in distinctive cat-like crying sounds in infants, developmental delays, and intellectual disabilities. Phelan-McDermid syndrome is caused by a deletion or mutation of the terminal end of the long arm of chromosome 13 (13q), leading to developmental delays, intellectual disability, absent or delayed speech, and autistic behaviors.

It's important to note that while some genetic disorders are associated with specific chromosomal abnormalities, many factors can contribute to the development and expression of these conditions, including environmental influences and interactions between multiple genes.

Forkhead transcription factors (FOX) are a family of proteins that play crucial roles in the regulation of gene expression through the process of binding to specific DNA sequences, thereby controlling various biological processes such as cell growth, differentiation, and apoptosis. These proteins are characterized by a conserved DNA-binding domain, known as the forkhead box or FOX domain, which adopts a winged helix structure that recognizes and binds to the consensus sequence 5'-(G/A)(T/C)AA(C/A)A-3'.

The FOX family is further divided into subfamilies based on the structure of their DNA-binding domains, with each subfamily having distinct functions. For example, FOXP proteins are involved in brain development and function, while FOXO proteins play a key role in regulating cellular responses to stress and metabolism. Dysregulation of forkhead transcription factors has been implicated in various diseases, including cancer, diabetes, and neurodegenerative disorders.

An oncogene protein fusion is a result of a genetic alteration in which parts of two different genes combine to create a hybrid gene that can contribute to the development of cancer. This fusion can lead to the production of an abnormal protein that promotes uncontrolled cell growth and division, ultimately resulting in a malignant tumor. Oncogene protein fusions are often caused by chromosomal rearrangements such as translocations, inversions, or deletions and are commonly found in various types of cancer, including leukemia and sarcoma. These genetic alterations can serve as potential targets for cancer diagnosis and therapy.

Desmin is a type of intermediate filament protein that is primarily found in the cardiac and skeletal muscle cells, as well as in some types of smooth muscle cells. It is an important component of the cytoskeleton, which provides structural support to the cell and helps maintain its shape. Desmin plays a crucial role in maintaining the integrity of the sarcomere, which is the basic contractile unit of the muscle fiber. Mutations in the desmin gene can lead to various forms of muscular dystrophy and other inherited muscle disorders.

Human chromosome pair 2 consists of two rod-shaped structures present in the nucleus of each cell of the human body. Each member of the pair contains thousands of genes and other genetic material, encoded in the form of DNA molecules. Chromosomes are the physical carriers of inheritance, and human cells typically contain 23 pairs of chromosomes for a total of 46 chromosomes.

Chromosome pair 2 is one of the autosomal pairs, meaning that it is not a sex chromosome (X or Y). Each member of chromosome pair 2 is approximately 247 million base pairs in length and contains an estimated 1,000-1,300 genes. These genes play crucial roles in various biological processes, including development, metabolism, and response to environmental stimuli.

Abnormalities in chromosome pair 2 can lead to genetic disorders, such as cat-eye syndrome (CES), which is characterized by iris abnormalities, anal atresia, hearing loss, and intellectual disability. This disorder arises from the presence of an extra copy of a small region on chromosome 2, resulting in partial trisomy of this region. Other genetic conditions associated with chromosome pair 2 include proximal 2q13.3 microdeletion syndrome and Potocki-Lupski syndrome (PTLS).

Vaginal neoplasms refer to abnormal growths or tumors in the vagina. These growths can be benign (non-cancerous) or malignant (cancerous). The two main types of vaginal neoplasms are:

1. Vaginal intraepithelial neoplasia (VAIN): This is a condition where the cells on the inner lining of the vagina become abnormal but have not invaded deeper tissues. VAIN can be low-grade or high-grade, depending on the severity of the cell changes.
2. Vaginal cancer: This is a malignant tumor that arises from the cells in the vagina. The two main types of vaginal cancer are squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma is the most common type, accounting for about 85% of all cases.

Risk factors for vaginal neoplasms include human papillomavirus (HPV) infection, smoking, older age, history of cervical cancer or precancerous changes, and exposure to diethylstilbestrol (DES) in utero. Treatment options depend on the type, stage, and location of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Combined modality therapy (CMT) is a medical treatment approach that utilizes more than one method or type of therapy simultaneously or in close succession, with the goal of enhancing the overall effectiveness of the treatment. In the context of cancer care, CMT often refers to the combination of two or more primary treatment modalities, such as surgery, radiation therapy, and systemic therapies (chemotherapy, immunotherapy, targeted therapy, etc.).

The rationale behind using combined modality therapy is that each treatment method can target cancer cells in different ways, potentially increasing the likelihood of eliminating all cancer cells and reducing the risk of recurrence. The specific combination and sequence of treatments will depend on various factors, including the type and stage of cancer, patient's overall health, and individual preferences.

For example, a common CMT approach for locally advanced rectal cancer may involve preoperative (neoadjuvant) chemoradiation therapy, followed by surgery to remove the tumor, and then postoperative (adjuvant) chemotherapy. This combined approach allows for the reduction of the tumor size before surgery, increases the likelihood of complete tumor removal, and targets any remaining microscopic cancer cells with systemic chemotherapy.

It is essential to consult with a multidisciplinary team of healthcare professionals to determine the most appropriate CMT plan for each individual patient, considering both the potential benefits and risks associated with each treatment method.

Translocation, genetic, refers to a type of chromosomal abnormality in which a segment of a chromosome is transferred from one chromosome to another, resulting in an altered genome. This can occur between two non-homologous chromosomes (non-reciprocal translocation) or between two homologous chromosomes (reciprocal translocation). Genetic translocations can lead to various clinical consequences, depending on the genes involved and the location of the translocation. Some translocations may result in no apparent effects, while others can cause developmental abnormalities, cancer, or other genetic disorders. In some cases, translocations can also increase the risk of having offspring with genetic conditions.

A Sertoli-Leydig cell tumor is a rare type of sex cord-stromal tumor that develops in the ovaries. These tumors arise from the cells that produce hormones and help to form and maintain the ovarian tissue. Sertoli-Leydig cell tumors can occur in people of any age but are most commonly found in women between the ages of 20 and 40.

These tumors can be functional, meaning they produce hormones, or nonfunctional. Functional Sertoli-Leydig cell tumors may cause symptoms related to the production of male hormones (androgens), such as excess facial hair, a deepened voice, and irregular menstrual periods. Nonfunctional tumors typically do not cause any specific symptoms and are often found during routine pelvic examinations or imaging studies performed for other reasons.

Sertoli-Leydig cell tumors are usually slow-growing and can vary in size. Most of these tumors are benign (not cancerous), but some can be malignant (cancerous) and may spread to other parts of the body. Treatment typically involves surgical removal of the tumor, and additional therapies such as chemotherapy or radiation therapy may be recommended depending on the stage and grade of the tumor. Regular follow-up care is essential to monitor for any recurrence of the tumor.

Myogenin is defined as a protein that belongs to the family of myogenic regulatory factors (MRFs). These proteins play crucial roles in the development, growth, and repair of skeletal muscle cells. Myogenin is specifically involved in the differentiation and fusion of myoblasts to form multinucleated myotubes, which are essential for the formation of mature skeletal muscle fibers. It functions as a transcription factor that binds to specific DNA sequences, thereby regulating the expression of genes required for muscle cell differentiation. Myogenin also plays a role in maintaining muscle homeostasis and may contribute to muscle regeneration following injury or disease.

MyoD protein is a member of the family of muscle regulatory factors (MRFs) that play crucial roles in the development and regulation of skeletal muscle. MyoD is a transcription factor, which means it binds to specific DNA sequences and helps control the transcription of nearby genes into messenger RNA (mRNA).

MyoD protein is encoded by the MYOD1 gene and is primarily expressed in skeletal muscle cells, where it functions as a master regulator of muscle differentiation. During myogenesis, MyoD is activated and initiates the expression of various genes involved in muscle-specific functions, such as contractile proteins and ion channels.

MyoD protein can also induce cell cycle arrest and promote the differentiation of non-muscle cells into muscle cells, a process known as transdifferentiation. This property has been explored in regenerative medicine for potential therapeutic applications.

In summary, MyoD protein is a key regulator of skeletal muscle development, differentiation, and maintenance, and it plays essential roles in the regulation of gene expression during myogenesis.

Vincristine is an antineoplastic agent, specifically a vinca alkaloid. It is derived from the Madagascar periwinkle plant (Catharanthus roseus). Vincristine binds to tubulin, a protein found in microtubules, and inhibits their polymerization, which results in disruption of mitotic spindles leading to cell cycle arrest and apoptosis (programmed cell death). It is used in the treatment of various types of cancer including leukemias, lymphomas, and solid tumors. Common side effects include peripheral neuropathy, constipation, and alopecia.

A cell line that is derived from tumor cells and has been adapted to grow in culture. These cell lines are often used in research to study the characteristics of cancer cells, including their growth patterns, genetic changes, and responses to various treatments. They can be established from many different types of tumors, such as carcinomas, sarcomas, and leukemias. Once established, these cell lines can be grown and maintained indefinitely in the laboratory, allowing researchers to conduct experiments and studies that would not be feasible using primary tumor cells. It is important to note that tumor cell lines may not always accurately represent the behavior of the original tumor, as they can undergo genetic changes during their time in culture.

Thoracic neoplasms refer to abnormal growths or tumors that develop in the thorax, which is the area of the body that includes the chest and lungs. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Malignant thoracic neoplasms are often referred to as lung cancer, but they can also include other types of cancer such as mesothelioma, thymoma, and esophageal cancer.

Thoracic neoplasms can cause various symptoms depending on their location and size. Common symptoms include coughing, chest pain, shortness of breath, hoarseness, and difficulty swallowing. Treatment options for thoracic neoplasms depend on the type, stage, and location of the tumor, as well as the patient's overall health. Treatment may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

'Tumor cells, cultured' refers to the process of removing cancerous cells from a tumor and growing them in controlled laboratory conditions. This is typically done by isolating the tumor cells from a patient's tissue sample, then placing them in a nutrient-rich environment that promotes their growth and multiplication.

The resulting cultured tumor cells can be used for various research purposes, including the study of cancer biology, drug development, and toxicity testing. They provide a valuable tool for researchers to better understand the behavior and characteristics of cancer cells outside of the human body, which can lead to the development of more effective cancer treatments.

It is important to note that cultured tumor cells may not always behave exactly the same way as they do in the human body, so findings from cell culture studies must be validated through further research, such as animal models or clinical trials.

Pelvic neoplasms refer to abnormal growths or tumors located in the pelvic region. These growths can be benign (non-cancerous) or malignant (cancerous). They can originate from various tissues within the pelvis, including the reproductive organs (such as ovaries, uterus, cervix, vagina, and vulva in women; and prostate, testicles, and penis in men), the urinary system (kidneys, ureters, bladder, and urethra), the gastrointestinal tract (colon, rectum, and anus), as well as the muscles, nerves, blood vessels, and other connective tissues.

Malignant pelvic neoplasms can invade surrounding tissues and spread to distant parts of the body (metastasize). The symptoms of pelvic neoplasms may vary depending on their location, size, and type but often include abdominal or pelvic pain, bloating, changes in bowel or bladder habits, unusual vaginal bleeding or discharge, and unintentional weight loss. Early detection and prompt treatment are crucial for improving the prognosis of malignant pelvic neoplasms.

Neoplastic gene expression regulation refers to the processes that control the production of proteins and other molecules from genes in neoplastic cells, or cells that are part of a tumor or cancer. In a normal cell, gene expression is tightly regulated to ensure that the right genes are turned on or off at the right time. However, in cancer cells, this regulation can be disrupted, leading to the overexpression or underexpression of certain genes.

Neoplastic gene expression regulation can be affected by a variety of factors, including genetic mutations, epigenetic changes, and signals from the tumor microenvironment. These changes can lead to the activation of oncogenes (genes that promote cancer growth and development) or the inactivation of tumor suppressor genes (genes that prevent cancer).

Understanding neoplastic gene expression regulation is important for developing new therapies for cancer, as targeting specific genes or pathways involved in this process can help to inhibit cancer growth and progression.

Dactinomycin is an antineoplastic antibiotic, which means it is used to treat cancer. It is specifically used to treat certain types of testicular cancer, Wilms' tumor (a type of kidney cancer that occurs in children), and some gestational trophoblastic tumors (a type of tumor that can develop in the uterus after pregnancy). Dactinomycin works by interfering with the DNA in cancer cells, which prevents them from dividing and growing. It is often used in combination with other chemotherapy drugs as part of a treatment regimen.

Dactinomycin is administered intravenously (through an IV) and its use is usually limited to hospitals or specialized cancer treatment centers due to the need for careful monitoring during administration. Common side effects include nausea, vomiting, and hair loss. More serious side effects can include bone marrow suppression, which can lead to an increased risk of infection, and tissue damage at the site where the drug is injected. Dactinomycin can also cause severe allergic reactions in some people.

It's important to note that dactinomycin should only be used under the supervision of a qualified healthcare professional, as its use requires careful monitoring and management of potential side effects.

A gene fusion, also known as a chromosomal translocation or fusion gene, is an abnormal genetic event where parts of two different genes combine to create a single, hybrid gene. This can occur due to various mechanisms such as chromosomal rearrangements, deletions, or inversions, leading to the formation of a chimeric gene with new and often altered functions.

Gene fusions can result in the production of abnormal fusion proteins that may contribute to cancer development and progression by promoting cell growth, inhibiting apoptosis (programmed cell death), or activating oncogenic signaling pathways. In some cases, gene fusions are specific to certain types of cancer and serve as valuable diagnostic markers and therapeutic targets for personalized medicine.

Enterovirus A, Human is a type of enterovirus that infects humans. Enteroviruses are small, single-stranded RNA viruses that belong to the Picornaviridae family. There are over 100 different types of enteroviruses, and they are divided into several species, including Enterovirus A, B, C, D, and Rhinovirus.

Enterovirus A includes several important human pathogens, such as polioviruses (which have been largely eradicated thanks to vaccination efforts), coxsackieviruses, echoviruses, and enterovirus 71. These viruses are typically transmitted through the fecal-oral route or respiratory droplets and can cause a range of illnesses, from mild symptoms like fever, rash, and sore throat to more severe diseases such as meningitis, encephalitis, myocarditis, and paralysis.

Poliovirus, which is the most well-known member of Enterovirus A, was responsible for causing poliomyelitis, a highly infectious disease that can lead to irreversible paralysis. However, due to widespread vaccination programs, wild poliovirus transmission has been eliminated in many parts of the world, and only a few countries still report cases of polio caused by vaccine-derived viruses.

Coxsackieviruses and echoviruses can cause various symptoms, including fever, rash, mouth sores, muscle aches, and respiratory illnesses. In some cases, they can also lead to more severe diseases such as meningitis or myocarditis. Enterovirus 71 is a significant pathogen that can cause hand, foot, and mouth disease, which is a common childhood illness characterized by fever, sore throat, and rash on the hands, feet, and mouth. In rare cases, enterovirus 71 can also lead to severe neurological complications such as encephalitis and polio-like paralysis.

Prevention measures for enterovirus A infections include good hygiene practices, such as washing hands frequently, avoiding close contact with sick individuals, and practicing safe food handling. Vaccination is available for poliovirus and can help prevent the spread of vaccine-derived viruses. No vaccines are currently available for other enterovirus A infections, but research is ongoing to develop effective vaccines against these viruses.

Pulmonary blastoma is a rare and aggressive type of lung cancer that primarily affects adults, but it can also occur in children. It's characterized by the rapid growth of primitive, undifferentiated cells that form tumors in the lungs. There are two main types of pulmonary blastomas:

1. Pleuropulmonary blastoma (PPB): This type is more common in children and adolescents. PPB can be further divided into three subtypes based on the age at diagnosis and the extent of tumor spread: Type I, Type II, and Type III. Types II and III are more aggressive and have a higher risk of metastasis compared to Type I.
2. Lung sarcomatoid carcinoma with pulmonary blastomatous components (LSC-PBC): This type is primarily found in adults and is considered a variant of lung sarcomatoid carcinoma, which is an aggressive subtype of non-small cell lung cancer. LSC-PBC contains both epithelial and mesenchymal elements, with the latter showing blastomatous features.

Both types of pulmonary blastomas have a poor prognosis due to their rapid growth and high likelihood of metastasis. Treatment typically involves surgical resection, chemotherapy, and radiation therapy. However, given the rarity of this condition, treatment options may vary depending on individual cases and access to specialized care.

Nephroblastoma overexpressed protein, also known as NOV or CCN3, is a member of the CCN family of proteins that are involved in cell growth, differentiation, and migration. It was originally identified as being highly expressed in nephroblastoma (also known as Wilms' tumor), a type of kidney cancer that typically affects children. NOV has been found to play a role in various biological processes, including angiogenesis, cell adhesion, and apoptosis. It can act as both a positive and negative regulator of cell growth and differentiation, depending on the context. Abnormal expression of NOV has been implicated in several types of cancer, including nephroblastoma, breast cancer, and prostate cancer.

... is also known as PAX-fusion negative or fusion-negative rhabdomyosarcoma, as tumors of this subtype ... When examining embryonal rhabdomyosarcoma tumors vs. alveolar rhabdomyosarcoma tumors, a 2013 study had discovered that there ... Embryonal rhabdomyosarcoma is generally associated with better prognosis than alveolar rhabdomyosarcoma, with a five-year ... The heterogenous structure resembles striated muscle at various embryonal developmental stages. Embryonal rhabdomyosarcoma can ...
... or botryoid sarcoma is a subtype of embryonal rhabdomyosarcoma, that can be observed in the walls of hollow ... Reynolds E, Logani S, Moller K, Horowitz I (2006). "Embryonal rhabdomyosarcoma of the uterus in a postmenopausal woman. Case ... Piver M, Rose P (1988). "Long-term follow-up and complications of infants with vulvovaginal embryonal rhabdomyosarcoma treated ... Hilgers R (1975). "Pelvic exenteration for vaginal embryonal rhabdomyosarcoma: a review". Obstet Gynecol. 45 (2): 175-80. PMID ...
Outlier case reports have been presented, including the aggressive prognosis of embryonal rhabdomyosarcoma and the simultaneous ... Balitzer D, McCalmont TH, Horvai AE (2015-12-10). "Adipocyte-Like Differentiation in a Posttreatment Embryonal Rhabdomyosarcoma ... Extensive research is needed for a more detailed report; however, embryonal rhabdomyosarcoma and rhabdomyoblast differentiation ... that the neoplasm may be a variant embryonal rhabdomyosarcoma. A 'nephroblastoma, also referred to as Wilms' tumor, arises from ...
"Orbital embryonal rhabdomyosarcoma in association with neurofibromatosis type 1". Ophthalmic Plast Reconstr Surg. 23 (2): 147-8 ... "Primary ophthalmic rhabdomyosarcoma in 33 patients". Trans Am Ophthalmol Soc. 99: 133-42, discussion 142-3. PMC 1359004. PMID ... "Clinical spectrum of primary ophthalmic rhabdomyosarcoma". Ophthalmology. 108 (12): 2284-92. doi:10.1016/s0161-6420(01)00840-5 ...
Tiffin N, Williams RD, Shipley J, Pritchard-Jones K (July 2003). "PAX7 expression in embryonal rhabdomyosarcoma suggests an ... A link to the metastatic potential of embryonal rhabdomyosarcoma and cutaneous malignant melanoma?". Histology and ... "In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma" (PDF). Human Molecular Genetics ... "PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's ...
Lin TY, Chu C, Chiu CH (October 2002). "Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells ...
Lin TY, Chu C, Chiu CH (October 2002). "Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells ...
It is expressed at higher levels in alveolar rhabdomyosarcoma than in embryonal rhabdomyosarcoma. In the brain, RMST is ... Rhabdomyosarcoma 2 associated transcript (RMST) is a long non-coding RNA. In humans, it is located on chromosome 12q21. ... "Identification of a novel gene NCRMS on chromosome 12q21 with differential expression between rhabdomyosarcoma subtypes". ...
The four subtypes are embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma, pleomorphic rhabdomyosarcoma, and spindle-cell/ ... Pleomorphic rhabdomyosarcoma (undifferentiated rhabdomyosarcoma), also known as anaplastic rhabdomyosarcoma, is defined by the ... embryonal, alveolar, pleomorphic, and spindle-cell/sclerosing.[citation needed] Embryonal rhabdomyosarcoma (ERMS) is the most ... Embryonal rhabdomyosarcoma is the most common type and comprises about 60% of cases. Outcomes vary considerably, with five-year ...
... is a subtype of embryonal rhabdomyosarcoma first described by Cavazzana, Schmidt and Ninfo in ... This subtype has a more favorable clinical course and prognosis than usual embryonal rhabdomyosarcoma. Spindle cell ... Cavazzana, A. O.; D. Schmidt; V. Ninfo (1992). "Spindle cell rhabdomyosarcoma: a prognostically favorable variant of ... rhabdomyosarcoma typically occurs in young males and most commonly occurs in paratesticular soft tissue, followed by the head ...
2004). "Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma". Histol. ...
"Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas ... Alveolar rhabdomyosarcoma (ARMS) is a subtype of the rhabdomyosarcoma soft tissue cancer family whose lineage is from ... "Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on ... March 1995). "The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent ...
2 cases of Embryonal rhabdomyosarcoma, and 2 cases of pleomorphic rhabdomyosarcoma. Rhabdomyosarcoma is a highly malignant form ... The 10 human rhabdomyosarcoma tumor exhibited decreased levels of methylation of CpG islands upstream of the first FGFR1 exon. ... In addition, a single case of rhabdomyosarcoma tumor was found express co-amplified FOXO1 gene at 13q14 and FGFR1 gene at 8p11 ... Elevated expression of FGFR1 protein was detected in 10 of 10 human Rhabdomyosarcoma tumors and 4 of 4 human cell lines derived ...
... include visualizing the nonspecific paratesticular masses which can mimic malignancies such as rhabdomyosarcoma or embryonal ...
... a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild- ...
Similar studies were carried out to diagnose neuroblastoma and rhabdomyosarcomas. They were also the first to demonstrate the ... They defined malignant fibrous histiocytoma as a sarcoma composed of tissue histiocytes, which are embryonal forms of ...
2003), "Resemblance to embryonal tissue", Holland-Frei Cancer Medicine (6th ed.), Hamilton, Ontario, Canada: BC Decker, ISBN 1- ... MEM is part of a group of small round blue cell tumors which includes neuroblastoma, rhabdomyosarcoma, non-Hodgkin's lymphoma, ... Mesenchymal elements, represented by rhabdomyosarcoma, were the dominant component in the majority of cases (5/6) while ... Translocations in Rhabdomyosarcoma without the Canonical PAX-FOXO1 fuse PAX3 to Members of the Nuclear Receptor Transcriptional ...
Introduction of miR-1 and miR-133a into an embryonal rhabdomyosarcoma-derived cell line is cytostatic, which suggested a strong ... Rhabdomyosarcoma is the most common soft tissue sarcoma in children. Since the tumor results from undifferentiated cells, ... September 2010). "Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells". ... October 2009). "MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development". The Journal of Biological Chemistry. ...
... alveolar and embryonal) rhabdomyosarcoma. Several oncogenes and tumor suppressor genes are epigenetically altered in sarcomas. ... and rhabdomyosarcoma. Drug targeting and inhibition of EZH2 in Ewing's sarcoma, or of LSD1 in several sarcomas, inhibits tumor ... and rhabdomyosarcoma". Human Pathology. 43 (8): 1300-1307. doi:10.1016/j.humpath.2011.10.010. PMID 22245111. Tam, Kit W.; Zhang ... and expression of the EZH2 component of the PRC2 complex is altered in Ewing's sarcoma and rhabdomyosarcoma. Similarly, ...
... embryonal rhabdomyosarcoma). However, PAX3 is also expressed in other cancer types without a clear relationship to a PAX3- ... Alveolar rhabdomyosarcoma (ARMS) is an aggressive soft tissue sarcoma that occurs in children and is usually characterized by a ... Olanich ME, Barr FG (2013). "A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma". review. Expert ... Barr FG (September 2001). "Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma". review. Oncogene. ...
... types Adenoma of minor vestibular glands Mixed Tumors of the vulva Tumors of skin appendage origin Embryonal rhabdomyosarcoma ( ...
... rhabdomyosarcoma, alveolar MeSH C04.557.450.590.550.660.675 - rhabdomyosarcoma, embryonal MeSH C04.557.450.590.775 - sarcoma, ... rhabdomyosarcoma, alveolar MeSH C04.557.450.795.550.660.675 - rhabdomyosarcoma, embryonal MeSH C04.557.450.795.560 - ... embryonal MeSH C04.557.465.220 - chordoma MeSH C04.557.465.280 - dermoid cyst MeSH C04.557.465.330 - germinoma MeSH C04.557. ...
... alveolar Rhabdomyosarcoma, embryonal Rheumatic fever Rheumatism Rheumatoid arthritis Rheumatoid purpura Rheumatoid vasculitis ... Rhabdomyomatous dysplasia cardiopathy genital anomalies Rhabdomyosarcoma Rhabdomyosarcoma 1 Rhabdomyosarcoma 2 Rhabdomyosarcoma ...
... the more common fetal and embryonal types do not Merkel cell carcinoma Mesenchymal chondrosarcoma Endometrial stromal ... Desmoplastic small-round-cell tumour Ewing sarcoma/PNET Neuroblastoma Medulloblastoma Rhabdomyosarcoma Synovial sarcoma ...
... or umbilical hernia Embryonal tumor (e.g., Wilms tumor, hepatoblastoma, neuroblastoma, rhabdomyosarcoma) in childhood ... rhabdomyosarcoma, and mesoblastic nephroma. Wilms tumor, hepatoblastoma, and mesoblastic nephroma can usually be cured if ...
GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis. Oncotarget. ... including rhabdomyosarcoma, osteosarcoma, neuroblastoma, and ovarian cancer. Arsenic Trioxide (ATO) directly binds to GLI1 and ...
... may refer to: Erms, a river of Germany Electronic Resource Management System Embryonal rhabdomyosarcoma Emissions ...
... adult type Pleomorphic rhabdomyosarcoma, NOS M8902/3 Mixed type rhabdomyosarcoma Mixed embryonal rhabdomyosarcoma and alveolar ... NOS Embryonal rhabdomyosarcoma, pleomorphic Sarcoma botryoides Botryoid sarcoma M8912/3 Spindle cell rhabdomyosarcoma M8920/3 ... nonseminomatous M9070/3 Embryonal carcinoma, NOS Embryonal adenocarcinoma M9071/3 Yolk sac tumor Endodermal sinus tumor ... NOS Embryonal teratoma Teratoblastoma, malignant Immature teratoma, malignant or NOS M9081/3 Teratocarcinoma Mixed embryonal ...
... embryonal rhabdomyosarcoma - embryonal tumor - embryonic - EMD 121974 - emitefur - emodin - enalapril - encephalopathy - ... rhabdomyosarcoma - rhizoxin - ribavirin - ribonucleotide reductase inhibitor - rifampin - risedronate - ritonavir - rituximab ...
Rhabdomyosarcoma is treated with surgery, radiotherapy, or chemotherapy. The majority of rhabdomyosarcoma patients have a 50-85 ... embryonal, alveolar, pleomorphic, and spindle cell/sclerosing) Hemangioendothelioma (includes the following varieties: retiform ... Wexler L (2004). "Rhabdomyosarcoma". ESUN. 1 (4). Retrieved 19 October 2011. Osteosarcoma Treatment & Management~treatment at ... Liposarcoma Treatment & Management~treatment at eMedicine "Rhabdomyosarcoma". Boston Children's Hospital. ...
... for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the ... and a separate report in 2011 on improving outcomes for patients with low-risk embryonal rhabdomyosarcoma. The Intergroup ... The Intergroup Rhabdomyosarcoma Study Group (IRS) was a U.S. and Canadian clinical trial cooperative group created with the ... "The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the ...
Embryonal rhabdomyosarcoma is also known as PAX-fusion negative or fusion-negative rhabdomyosarcoma, as tumors of this subtype ... When examining embryonal rhabdomyosarcoma tumors vs. alveolar rhabdomyosarcoma tumors, a 2013 study had discovered that there ... Embryonal rhabdomyosarcoma is generally associated with better prognosis than alveolar rhabdomyosarcoma, with a five-year ... The heterogenous structure resembles striated muscle at various embryonal developmental stages. Embryonal rhabdomyosarcoma can ...
Inhibition of the lysine methyltransferase G9a blocks oncogenic phenotypes in embryonal rhabdomyosarcoma. ... 2010) Impaired wnt signaling in embryonal Rhabdomyosarcoma cells from p53/c-fos double mutant mice The American Journal of ... Embryonal rhabdomyosarcoma (ERMS) accounts for the majority (~60%) of all RMS cases. No single genetic lesion is linked to ERMS ... 2017) The NOTCH1/SNAIL1/MEF2C pathway regulates growth and Self-Renewal in embryonal Rhabdomyosarcoma Cell Reports 19:2304-2318 ...
2016). MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma. ... MiR-101EZH2Histone methyltransferasesPolycomb proteinsRhabdomyosarcomaCell motilityCell proliferationAnchorage-independent ... Abstract Background Rhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma arising from myogenic precursors that have lost ... reported that EZH2 inhibition induces cell cycle arrest followed by myogenic differentiation of RMS cells of the embryonal ...
Retrieved from "https://librepathology.org/w/index.php?title=Embryonal_rhabdomyosarcoma&oldid=8358" ...
Dive into the research topics of Embryonal Rhabdomyosarcoma of the Conjunctiva: A Clinicopathologic and Immunohistochemical ...
A poorly circumscribed morphologic variant of rhabdomyosarcoma. It is characterized by the presence of primitive skeletal ... Bladder Embryonal Rhabdomyosarcoma. *Botryoid-Type Embryonal Rhabdomyosarcoma*Adult botryoid rhabdomyosarcoma*Adult vagina ... Embryonal neoplasm*Embryonal rhabdomyosarcoma*Anaplastic Embryonal Rhabdomyosarcoma. * ... Auricular embryonal rhabdomyosarcoma.. Arredondo Montero J, Bronte Anaut M, Hernández-Martín S, López-Gutiérrez JC. World J ...
Sarcoma botryoides (embryonal rhabdomyosarcoma). Although this tumor is rare, it is the most common vaginal cancer in children ...
Embryonal Rhabdomyosarcoma of Orbit; embryonal rhabdomyosarcoma of orbit; Embryonal Rhabdomyosarcoma of the Orbit; embryonal ... 45 GyRBE for group III orbital embryonal rhabdomyosarcoma.. Indelicato DJ, Rotondo RL, Mailhot Vega RB, Uezono H, Bradfield S, ... 45 GyRBE for group III orbital embryonal rhabdomyosarcoma.. Indelicato DJ, Rotondo RL, Mailhot Vega RB, Uezono H, Bradfield S, ... for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the ...
"Focally anaplastic embryonal rhabdomyosarcoma". Show Diagnoses. Week 218: Case 3. Diagnosis: Focally anaplastic embryonal ...
Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma:a report from the Childrens ... Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma:a report from the Childrens ... The spectrum of tumors found in Gorlin Syndrome includes basal cell carcinoma, medulloblastoma, and rarely, rhabdomyosarcoma ( ... rhabdomyosarcoma,sarcoma,signal transduction,transcription factors,sdg 3 - good health and well-being ,/dk/atira/pure/ ...
The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation ... The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation ... Here we report that YAP1 activity is elevated in human embryonal rhabdomyosarcoma (ERMS). In mice, sustained YAP1 hyperactivity ... Here we report that YAP1 activity is elevated in human embryonal rhabdomyosarcoma (ERMS). In mice, sustained YAP1 hyperactivity ...
Rhabdomyosarcoma is a cancerous (malignant) tumor of the muscles that are attached to the bones. This cancer mostly affects ... Rhabdomyosarcoma is a cancerous (malignant) tumor of the muscles that are attached to the bones. This cancer mostly affects ... Soft tissue cancer - rhabdomyosarcoma; Soft tissue sarcoma; Alveolar rhabdomyosarcoma; Embryonal rhabdomyosarcoma; Sarcoma ... The cause of rhabdomyosarcoma is unknown. It is a rare tumor with only several hundred new cases per year in the United States. ...
The most common kind of soft tissue sarcoma in children is rhabdomyosarcoma, which are tumors that arise from muscle tissue and ... 2 major forms of rhabdomyosarcomas. *Embryonal rhabdomyosarcoma *This form is more common in the: *Head ... Alveolar rhabdomyosarcoma *This kind of rhabdomyosarcoma is more common in the: *Large muscles of the trunk ... Although the specific risk factors for rhabdomyosarcoma are unknown, there is an increased risk of rhabdomyosarcoma due to ...
... Publication , Journal Article ... "The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma." Cell Rep 19, no. 11 (June 13 ... "The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma." Cell Rep, vol. 19, no. 11, ... The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep. 2017 Jun 13;19(11): ...
Clinicopathologic along with survival fits of embryonal rhabdomyosarcoma driven simply by RAS/RAF mutations.. Posted on August ...
Embryonal Rhabdomyosarcoma of the Bladder. By Zhu R, Towbin RB, Schaefer CM, Towbin AJ ...
Embryonal Rhabdomyosarcoma: A Case Report Muntasir Mahbub, Nabila Mannan, Md Mazharul Shaheen, Manash Ranjan Chakraborti, AKM ...
Auricular embryonal rhabdomyosarcoma. Arredondo Montero J, Bronte Anaut M, Hernández-Martín S, López-Gutiérrez JC. Arredondo ...
... sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy in vitro and in vivo. Abstract. Treatment of ... sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy in vitro and in vivo. ... rhabdomyosarcoma (RMS), the most common a soft tissue sarcoma in childhood, provides intensive multimodal therapy, with ...
rhabdomyosarcoma has two forms:. - embryonal rhabdomyosarcoma:. - is the most common form of this tumor in children and young ... Rhabdomyosarcoma. Rhabdomyosarcoma. - See: Soft Tissue Menu. - Discussion:. - describes sarcomas of smooth muscle ( ... Factors predictive of mortality in pediatric extremity rhabdomyosarcoma.. Childhood Rhabdomyosarcoma of the trunk and ... leiomyosarcoma) & sarcomas of skeletal muscle (rhabdomyosarcoma);. - rhabdomyosarcomas make up 2/3 of pediatric soft-tissue ...
... human embryonal rhabdomyosarcoma cell culture; m, mosquito.. ‡Information uncertain for Ten Broeck strain sequenced in this ...
Embryonal is the most common type. Its most common in young children. ... What is rhabdomyosarcoma in children?. Rhabdomyosarcoma is a type of cancer. It starts in cells that should grow into skeletal ... Key Points About Rhabdomyosarcoma in Children. *Rhabdomyosarcoma is a rare type of cancer that starts in the cells that develop ... How can I help my child live with rhabdomyosarcoma?. A child with rhabdomyosarcoma needs ongoing care. Your child will be seen ...
Embryonal rhabdomyosarcoma is a vaginal tumor found in toddlers. It appears as a grape-like mass protruding from the vagina. ...
Rhabdomyosarcoma, Embryonal. 1. 2022. 102. 0.200. Why? RNA Polymerase II. 2. 2021. 544. 0.180. Why? ...
IX(a) Rhabdomyosarcoma and embryonal sarcoma 92 IX(b) Fibrosarcoma, neurofibrosar and oth fibromatous ne 93 IX(c) Kaposi ...
Embryonal rhabdomyosarcoma (ERMS) is the most common type. *ERMS tends to occur in younger children. Common sites include the ... Newly Diagnosed with Rhabdomyosarcoma. In Treatment for Rhabdomyosarcoma. After Treatment for Rhabdomyosarcoma ... Rhabdomyosarcoma. Rhabdomyosarcoma (RMS or rhabdo) is a tumor made up of cancerous cells that look like immature muscle cells ... Alveolar rhabdomyosarcoma (ARMS) makes up about 25-40% of RMS. This type is more commonly found in adolescents and often occurs ...
ERMS-embryonal rhabdomyosarcoma (RMS); ARMS-alveolar RMS; PRMS-pleomorphic RMS; SKM-skeletal muscle; GIST-gastrointestinal ...
Embryonal rhabdomyosarcoma. * Mesothelioma. * Pagets disease. * Soft tissue tumors of the vulva. * Superficial cervicovaginal ...
A Role for Notch in Self-renewal in Embryonal Rhabdomyosarcoma Massachusetts General Hospital / Myron Ignatius, PhD A Award ... A novel mouse model of rhabdomyosarcoma Vanderbilt University Medical Center / Chin Chiang, PhD Innovation Grants 2012 ...
  • ERMS accounts for 60% to 70% of rhabdomyosarcoma, the other being alveolar rhabdomyosarcoma (ARMS), also known as PAX-fusion positive or fusion-positive rhabdomyosarcoma. (wikipedia.org)
  • These two subtypes of rhabdomyosarcoma, ERMS and ARMS, also are caused by different genetic mutation pathways. (wikipedia.org)
  • When examining embryonal rhabdomyosarcoma tumors vs. alveolar rhabdomyosarcoma tumors, a 2013 study had discovered that there were more rates of mutation in ERMS tumors. (wikipedia.org)
  • Wnt signaling is downregulated in embryonal rhabdomyosarcoma (ERMS) and contributes to the block of differentiation. (elifesciences.org)
  • Embryonal rhabdomyosarcoma (ERMS) accounts for the majority (~60%) of all RMS cases. (elifesciences.org)
  • We previously reported that EZH2 inhibition induces cell cycle arrest followed by myogenic differentiation of RMS cells of the embryonal subtype (eRMS). (figshare.com)
  • Here we report that YAP1 activity is elevated in human embryonal rhabdomyosarcoma (ERMS). (elsevierpure.com)
  • However, mechanisms regulating TPC self-renewal are largely unknown, especially in embryonal rhabdomyosarcoma (ERMS)-a common pediatric cancer of muscle. (duke.edu)
  • Embryonal rhabdomyosarcoma (ERMS) is the most common type. (childrensoncologygroup.org)
  • Her research allowed for developing an easy PCR-based assay to phenotype embryonal (ERMS) and alveolar (ARMS) rhabdomyosarcoma based on the methylation of imprinted regions within DLK1-MEG3 locus. (louisville.edu)
  • Embryonal rhabdomyosarcoma is also known as PAX-fusion negative or fusion-negative rhabdomyosarcoma, as tumors of this subtype are unified by their lack of a PAX3-FOXO1 fusion oncogene (or other PAX fusions seen in alveolar rhabdomyosarcoma). (wikipedia.org)
  • These types of tumors are classified as embryonal rhabdomyosarcoma "because of their remarkable resemblance to developing embryonic and fetal skeletal muscle. (wikipedia.org)
  • The study had use whole genome sequencing to sequence the DNA from 16 RMS tumors and found that RAS pathway mutations tend to be more associated with intermediate and high-risk embryonal Rhabdomyosarcoma. (wikipedia.org)
  • The spectrum of tumors found in Gorlin Syndrome includes basal cell carcinoma, medulloblastoma, and rarely, rhabdomyosarcoma (RMS). (uea.ac.uk)
  • Rhabdomyosarcoma is a type of sarcoma made up of tumors that arise from muscle tissue and spread throughout the body. (medicinenet.com)
  • Children with genitourinary tract cancers may manifest with a painless scrotal lump (paratesticular tumors), a projecting grape-like mass in the vagina ("botryoid" rhabdomyosarcoma), blood in the urine (bladder tumors), or frequent urination , often with a burning sensation or hesitation. (medicinenet.com)
  • Rhabdomyosarcoma belongs to a group of tumors known as soft-tissue sarcomas and is the most common cancer in this group. (merckmanuals.com)
  • The p53 gene was examined in primary or metastatic tumors from six patients with rhabdomyosarcoma (RMS) and in five RMS cell lines by screening methods including single-strand conformation polymorphism analysis, the RNase protection assay, sequencing of complementary DNA subclones, and Southern blotting. (nih.gov)
  • Six original tumors were of embryonal histology, four alveolar, and one mixed. (nih.gov)
  • p53 mutations were identified in four of the six tumors or cell lines derived from tumors with embryonal histology and in one of the four with alveolar histology. (nih.gov)
  • Rhabdomyosarcoma is a member of the group of "small round blue cell" tumors, and must be distinguished from morphologically similar pediatric tumors. (umich.edu)
  • Testing can aid in distinguishing alveolar rhabdomyosarcoma from other similar tumors. (umich.edu)
  • Approximately 20% of tumors diagnosed as alveolar rhabdomyosarcoma based on histologic grounds have been found to be negative for a PAX/FOXO1 translocation or fusion transcript. (umich.edu)
  • These guidelines do not pertain to the management of gastrointestinal stroma tumors (GISTs), rhabdomyosarcoma, Ewing sarcoma, desmoplastic round cell tumors, and primitive neuroectodermal tumors. (medscape.com)
  • Embryonal rhabdomyosarcoma (EMRS) is a rare histological form of cancer in the connective tissue wherein the mesenchymally-derived malignant cells resemble the primitive developing skeletal muscle of the embryo. (wikipedia.org)
  • Abstract Background Rhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma arising from myogenic precursors that have lost their capability to differentiate into skeletal muscle. (figshare.com)
  • Rhabdomyosarcoma is a rare type of cancer that starts in the cells that develop into skeletal muscle cells. (childrensnational.org)
  • Rhabdomyosarcoma (RMS) is a malignant tumor with skeletal muscle cell morphology. (radiopaedia.org)
  • Rhabdomyosarcomas are thought not to arise from skeletal muscle, but rather to differentiate into a tumor that resembles skeletal muscle 7 . (radiopaedia.org)
  • Rhabdomyosarcoma is a cancer arising from embryonal mesenchymal cells that have potential to differentiate into skeletal muscle cells. (merckmanuals.com)
  • Is Rhabdomyosarcoma Soft Tissue Sarcoma? (medicinenet.com)
  • Treatment of rhabdomyosarcoma (RMS), the most common a soft tissue sarcoma in childhood, provides intensive multimodal therapy, with radiotherapy (RT) playing a critical role for local tumor control. (saludintegral.hn)
  • Scholars@Duke publication: The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. (duke.edu)
  • Embryonal rhabdomyosarcoma can be further divided into three subcategories: the botryoid, spindle cell, and not-otherwise-specified (NOS). (wikipedia.org)
  • The Horn-Enterline classification uses morphologic characteristics to divide rhabdomyosarcoma into the embryonal, alveolar, botryoid, and pleomorphic subtypes. (wikipedia.org)
  • The paternally imprinted DLK1-GTL2 locus is differentially methylated in embryonal and alveolar rhabdomyosarcomas. (louisville.edu)
  • The t(2;13)(q35;q14) translocation joins the PAX3 and FOXO1 (FKHR) genes in approximately 60% of alveolar rhabdomyosarcomas, while the less common t(1;13)(p36;q14) joins PAX7 with FOXO1 in approximately 20% of cases. (umich.edu)
  • This assay is expected to be positive in approximately 80% of all alveolar rhabdomyosarcomas. (umich.edu)
  • A poorly circumscribed morphologic variant of rhabdomyosarcoma. (nih.gov)
  • Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. (atlasgeneticsoncology.org)
  • Pediatric head and neck rhabdomyosarcoma: An analysis of treatment and survival in the United States (1975-2016). (nih.gov)
  • Clinicopathological analysis of head and neck rhabdomyosarcoma: A series of 10 cases and literature review. (nih.gov)
  • Rhabdomyosarcoma of the head and neck in children: review and update. (nih.gov)
  • Long term survival in rhabdomyosarcoma of head and neck. (minervamedica.it)
  • Embryonal occurs in the head and neck, or the genital or urinary organs. (curesarcoma.org)
  • As a result, the World Health Organization currently takes into account both molecular genetics and morphology to classify rhabdomyosarcoma into the embryonal, alveolar, spindle cell/sclerosing, and pleomorphic subtypes. (wikipedia.org)
  • Histologically, embryonal rhabdomyosarcoma commonly presents as alternating loose and dense patches of cells, including round cell and spindle cell components. (wikipedia.org)
  • Cancers that occur most frequently in affected individuals include a cancer of muscle tissue called rhabdomyosarcoma, a form of kidney cancer known as Wilms tumor, and a cancer of the blood-forming tissue known as leukemia. (nih.gov)
  • Rhabdomyosarcoma can occur in many places in the body. (medlineplus.gov)
  • Two recurrent and distinctive chromosomal translocations occur in alveolar rhabdomyosarcoma. (umich.edu)
  • Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: An analysis of 2,600 patients. (merckmanuals.com)
  • Clinicopathologic along with survival fits of embryonal rhabdomyosarcoma driven simply by RAS/RAF mutations. (thrombininhibitors.com)
  • Dr. Schneider's work led to the identification of changes in genomic imprinting of DLK1-MEG3 locus in rhabdomyosarcoma and acute myeloid leukemia (AML) and pointed to their role in diagnosis and patient survival prediction. (louisville.edu)
  • A Review of the Role of Cytogenetics in the Diagnosis of Orbital Rhabdomyosarcoma. (nih.gov)
  • Up to 20% of patients with rhabdomyosarcomas have metastases at the time of diagnosis 7 . (radiopaedia.org)
  • Call your provider if your child has symptoms of rhabdomyosarcoma. (medlineplus.gov)
  • The symptoms of rhabdomyosarcoma (RMS) might differ greatly depending on where the tumor develops. (medicinenet.com)
  • What are the symptoms of rhabdomyosarcoma in children? (childrensnational.org)
  • The symptoms of rhabdomyosarcoma are a lot like those of other, more common, health conditions. (childrensnational.org)
  • Rhabdomyosarcoma (RMS) is a soft tissue tumor derived from mesenchymal tissue with myogenic differentiation and associated with the embryogenesis of striated muscle. (biomedcentral.com)
  • Rhabdomyosarcoma is a cancerous (malignant) tumor of the muscles that are attached to the bones. (medlineplus.gov)
  • Wilms Tumor Wilms tumor is an embryonal cancer of the kidney composed of blastemal, stromal, and epithelial elements. (merckmanuals.com)
  • Childhood rhabdomyosarcoma treatment (PDQ) health professional version. (medlineplus.gov)
  • Rhabdomyosarcomas are the most common soft tissue tumor in children and account for 5-8% of childhood cancers 6,7 , and 19% of all pediatric soft tissue sarcomas 7 . (radiopaedia.org)
  • When present in the extremities in children, embryonal rhabdomyosarcomas may cause bowing of the adjacent long bones. (radiopaedia.org)
  • 3. Linardic CM, Wexler LH: Rhabdomyosarcoma: Epidemiology and Genetic Susceptibilty. (merckmanuals.com)
  • A case of congenital rhabdomyosarcoma. (nih.gov)
  • Embryonal rhabdomyosarcomas tend to be more homogeneous, whereas alveolar and pleomorphic rhabdomyosarcomas frequently have areas of necrosis 6 . (radiopaedia.org)
  • Rhabdomyosarcoma, mostly of the embryonic subtype is the tumor the most frequently encountered in CS. (atlasgeneticsoncology.org)
  • Many different chemotherapy drugs are active against rhabdomyosarcoma. (medlineplus.gov)
  • Intergroup Rhabdomyosarcoma Study-4 risk stratification was used, with treatment based on a multimodality-regimen with chemotherapy (Vincristine/Ifosfamide/Etoposide and Vincristine/Actinomycin-D/Cyclophosphamide) and appropriate local therapy. (ecancer.org)
  • Lymph node involvement is not characteristic of most sarcomas except rhabdomyosarcoma and synovial, clear cell, vascular, and epithelioid sarcomas. (medscape.com)
  • Embryonal rhabdomyosarcoma is the most common in young children but there has been report of a second age peak in adolescence years. (wikipedia.org)
  • Most children with rhabdomyosarcoma do not have any known risk factors. (medlineplus.gov)
  • With intensive treatment, most children with rhabdomyosarcoma are able to survive long-term. (medlineplus.gov)
  • What is rhabdomyosarcoma in children? (childrensnational.org)
  • Which children are at risk for rhabdomyosarcoma? (childrensnational.org)
  • How is rhabdomyosarcoma in children diagnosed? (childrensnational.org)
  • Two thirds of rhabdomyosarcomas are diagnosed in children 7 years of age. (merckmanuals.com)
  • Lizzy was diagnosed with Stage Four Embryonal rhabdomyosarcoma, a rare form of cancer found in children. (kxxv.com)
  • children born with high birth weights or larger than expected when born have increased risk of embryonal rhabdomyosarcoma. (curesarcoma.org)
  • Embryonal rhabdomyosarcoma results from copy number alterations as well as mutations in the RAS pathway. (wikipedia.org)
  • Preclinical studies have demonstrated that resistance to FGFR inhibitors can be acquired through mutations in the FGFR gatekeeper residue, as clinically observed for FGFR4 in embryonal rhabdomyosarcoma and neuroendocrine breast carcinomas. (rcsb.org)
  • Although the specific risk factors for rhabdomyosarcoma are unknown, there is an increased risk of rhabdomyosarcoma due to radiation exposure or the use of certain recreational drugs by the mother during pregnancy and certain genetic conditions. (medicinenet.com)
  • P3F and P7F were detected in 25/49 (51%) and 14/85 (16.5%) of alveolar and embryonal variants, respectively. (ecancer.org)
  • Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. (nih.gov)